Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

BeiGene in-licenses two clinical-stage oncology candidates

Oct. 20, 2011

New carbazole-linked hybrid antitumor agents prepared

Oct. 20, 2011

Lilly begins phase II study of LY-2510924 in SCLC

Oct. 20, 2011

CSIR presents new antitumor agents

Oct. 19, 2011

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Oct. 19, 2011

Orantinib advances through studies in NSCLC and breast cancer

Oct. 19, 2011

Halozyme discloses clinical results on new Herceptin formulation

Oct. 19, 2011

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Oct. 19, 2011

Interim first-in-human data released on two c-Met inhibitors

Oct. 19, 2011

AB Science recruits first patient in phase III masitinib trial

Oct. 18, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...